Antibody Manufacturing Xchange 2026

Welcome to hubXchange's Antibody Manufacturing Xchange Boston 2026.

This event brings together senior-level scientists and executives from the pharmaceutical and biotech sectors to tackle key challenges in Cell Line Development, Upstream Development, Downstream Processing & Purification, Formulation & Stability, and Quality Control & Characterization.

Attendees can engage in roundtable discussions, pre-booked 1:1 meetings, presentations, and networking sessions with top industry experts to foster collaboration and find innovative solutions to accelerate antibody manufacturing.

Take advantage of this unique, highly interactive meeting format designed for maximum engagement, collaboration, and networking.

Boston | Wednesday 29th April 2026 | 08:00am - 05:30pm

VIEW AGENDA REGISTER FOR FREE OUR PARTNERS EVENT INFORMATION

Why choose hubXchange?

Click the topic titles to find out more!

Loading

Registration

30 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization

Opening Address & Keynote Presentation:

30 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization

Cell Line Development

Cell line development strategies towards overcoming multispecific expression challenges

60 mins
- Cell Line Development
What attributes make multispecific antibodies a promising emerging class of therapeutic modalities? How does the structural complexity of multispecific antibodies, typically comprising three or more u ...

Jack Scarcelli, Senior Director, Head of Cell Line Development - Sanofi
Upstream Development

Developing a high-throughput early developability package to support the pipeline and AI model training

60 mins
- Upstream Development
How can we meet the growing demand for early developability assessment across expanding pipelines? What strategies enable testing more clones earlier in discovery without compromising data quality or ...

Gilad Kaplan, Director of Protein Analytics and Developability for Biologics Engineering, R&D team lead - AstraZeneca
Downstream Processing & Purification

Separating aggregates and fragments without reducing yield or affecting stability

60 mins
- Downstream Processing & Purification
How can optimized chromatographic techniques such as SEC or IEX be employed to effectively distinguish aggregates, fragments, and monomers while maintaining high resolution and recovery rates? How can ...

Deborah Moore-Lai, Vice President of Protein Sciences - ProFound Therapeutics
Formulation & Stability

Choosing buffers and stabilizers that prevent aggregation and degradation

60 mins
- Formulation & Stability
What criteria are used to select buffers/additives during mAb purification? Are they driven by process requirements (e.g. chromatography), and/or also to protect against further loss of quality attri ...

Satish Singh, Vice President, Drug Product Development - Astria Therapeutics
Quality Control & Characterization

Detecting variations in glycan profiles that affect efficacy or immunogenicity

60 mins
- Quality Control & Characterization
What level of glycan shift is considered clinically meaningful after pivotal trials, and how should that threshold be justified in the absence of new clinical data? When analytical comparability is ma ...

Feny Gunawan, Senior Director of CMC - Mediar Therapeutics

1-2-1 Meetings / Networking Break

25 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization

1-2-1 Meetings / Networking Break

30 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization

Morning Refreshments

10 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization

Cell Line Development

Balancing productivity with quality: Are we reaching the limits of cell line optimisation?

60 mins
- Cell Line Development
Are current cell line optimisation strategies approaching their biological or technological limits? How does pushing for higher productivity impact product quality attributes such as glycosylation and ...
Upstream Development

Balancing nutrient supply to maximize productivity without affecting product quality

60 mins
- Upstream Development
How can nutrient supply be optimized to maximize cell growth and productivity without compromising product quality? Which nutrients most strongly influence critical quality attributes such as glycosyl ...
Downstream Processing & Purification

Ensuring minimal HCP contamination to meet regulatory requirements

60 mins
- Downstream Processing & Purification
What are the primary sources of host cell protein (HCP) contamination throughout the manufacturing process? How sensitive and robust are current analytical methods for detecting low-level HCP impuriti ...
Formulation & Stability

Accurately forecasting long-term stability from accelerated data

60 mins
- Formulation & Stability
How reliably can accelerated stability studies predict long-term product behavior under real-time conditions? Which degradation pathways observed under accelerated conditions are truly representative ...
Quality Control & Characterization

Resolving acidic or basic variants that may influence stability or bioactivity

60 mins
- Quality Control & Characterization
Which acidic and basic variants are present, and what are their underlying root causes (e.g., deamidation, glycation, C-terminal lysine, sialylation)? How can analytical methods best separate, identif ...

Networking Lunch

60 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization

Spotlight Presentation:

30 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization

1-2-1 Meetings / Networking Break

30 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization

1-2-1 Meetings / Networking Break

30 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization

Afternoon Refreshments

10 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization

Cell Line Development

Poster Presentation: Balancing productivity with quality: Are we reaching the limits of cell line optimisation?

30 mins
- Cell Line Development
Balancing productivity and product quality remains a central challenge in biopharmaceutical manufacturing. Advances in cell line optimisation have delivered substantial gains in expression levels, yet ...
Upstream Development

Poster Presentation: Maintaining consistent growth and antibody quality from lab-scale to commercial-scale bioreactors

30 mins
- Upstream Development
Maintaining consistent cell growth and antibody quality during scale-up from lab-scale to commercial-scale bioreactors remains a critical challenge in biopharmaceutical development. Differences in mix ...
Downstream Processing & Purification

Poster Presentation: Balancing robust viral inactivation with product recovery

30 mins
- Downstream Processing & Purification
Maintaining consistent cell growth and antibody quality during scale-up from lab-scale to commercial-scale bioreactors remains a critical challenge in biopharmaceutical development. Differences in mix ...
Formulation & Stability

Poster Presentation: Preventing loss of activity or aggregation during storage and shipping

30 mins
- Formulation & Stability
Preventing loss of activity or aggregation during storage and shipping is essential to maintain the safety and efficacy of biopharmaceutical products. Proteins are inherently sensitive to environmenta ...
Quality Control & Characterization

Poster Presentation: Establishing reliable in vitro assays for antibody activity

30 mins
- Quality Control & Characterization
Establishing reliable in vitro assays for antibody activity is fundamental to demonstrating product potency, comparability, and consistency throughout development and manufacturing. Such assays must a ...

Cell Line Development

From lab to manufacturing: How do we ensure cell lines are adaptable to evolving processes at scale?

60 mins
- Cell Line Development
How can we ensure consistency in genetic integrity when implementing updated or intensified processes? What strategies can be employed to maintain robust product quality in an intensified process form ...

Christina Alves, Head of US Biologics Process Development - Takeda
Upstream Development

How can we accomplish early upstream development while racing to FIH?

60 mins
- Upstream Development
What aspects of a process can be established prior to clone selection or stability? How early can we supply representative material? What investments have demonstrated value for acceleration and eff ...

Rustin Shenkman, Director, Internal Cell Culture Development & Manufacture - Kiniksa Pharmaceuticals
Downstream Processing & Purification

Managing resin fouling and degradation while maintaining high purification efficiency

60 mins
- Downstream Processing & Purification
What are the primary mechanisms driving resin fouling and degradation during repeated purification cycles? How does resin aging impact binding capacity, selectivity, and overall purification efficienc ...
Formulation & Stability

Identifying conditions that trigger denaturation or chemical modifications

60 mins
- Formulation & Stability
Which formulation conditions (pH, ionic strength, excipients) most strongly trigger protein denaturation or chemical modification? How do environmental stresses such as temperature, light, agitation, ...
Quality Control & Characterization

Challenges of developing stable high‐concentration formulations for novel biologic modalities

60 mins
- Quality Control & Characterization
What issues are you faced with when developing high concentration formulations for novel modalities? What excipient(s) (amino acids, salts, surfactants, polymers) have you tested or considered to redu ...

Dmitry Gumerov, Senior Director, CMC, Pharmaceutical Sciences and Technology - Visterra Inc. (Otsuka company)

Drinks-Canape Reception

60 mins
- Cell Line Development
- Upstream Development
- Downstream Processing & Purification
- Formulation & Stability
- Quality Control & Characterization